ImexpharmSTC:IMP 98 Return-on-Tangible-Equity is 14.72% as of Mar. 2026, which is 23% above its 10-year median of 11.93. GuruFocus rates STC:IMP with a GF Score™ of 98/100 and a GF Value™ of ₫51,983.47 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 897 Drug Manufacturers companies, Imexpharm ranks better than 73.58% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Imexpharm's annualized net income for the quarter that ended in Mar. 2026 was ₫328,074 Mil. Imexpharm's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₫2,228,755 Mil. Therefore, Imexpharm's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 14.72%.
The historical rank and industry rank for Imexpharm's Return-on-Tangible-Equity or its related term are showing as below:
STC:IMP'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 9.44 Med: 11.93 Max: 16.75
Current: 16.75
During the past 13 years, Imexpharm's highest Return-on-Tangible-Equity was 16.75%. The lowest was 9.44%. And the median was 11.93%.
STC:IMP's Return-on-Tangible-Equity is ranked better than 73.58% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.89
vs STC:IMP: 16.75
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Imexpharm Return-on-Tangible-Equity Related Terms
Imexpharm Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Imexpharm's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STC:IMP vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imexpharm Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Imexpharm's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Imexpharm's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 14.72% mean?
Imexpharm (STC:IMP) has a Return-on-Tangible-Equity of 14.72% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Imexpharm and its competitors. This is 23% above median its historical median of 11.93. Over the past decade, Imexpharm's Return-on-Tangible-Equity has ranged from 9.44 to 16.75. According to the industry distribution chart, Imexpharm ranks #237 out of 897 companies in the Drug Manufacturers industry, placing it in the top 26.4%.
Is Imexpharm's Return-on-Tangible-Equity too high?
Imexpharm's current Return-on-Tangible-Equity of 14.72% is 23% above median its 10-year median of 11.93. Over the past 10 years, this metric has ranged from a low of 9.44 to a high of 16.75. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.89. Imexpharm's value of 14.72% is 86.6% above this industry median. Based on the distribution chart, Imexpharm ranks #237 out of 897 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Imexpharm has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Imexpharm ranks #237 out of 897 companies for Return-on-Tangible-Equity. This puts Imexpharm in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.89. Imexpharm's value of 14.72% is 86.6% above this benchmark. Historically, Imexpharm's own Return-on-Tangible-Equity has ranged from 9.44 to 16.75 over the past decade. While the company's 10-year median is 11.93 vs. the industry median of 7.89, Imexpharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.89, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imexpharm's current Return-on-Tangible-Equity of 14.72% is 86.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Imexpharm and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imexpharm's current Return-on-Tangible-Equity is 14.72%, which is 23% above median its own 10-year median of 11.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫51,983.47, compared to a current price of ₫41,200.00 — trading 20.7% below its estimated fair value. The current Return-on-Tangible-Equity is 14.72%, which is 23% above median its 10-year median of 11.93 and 86.6% above the Drug Manufacturers industry median of 7.89. Imexpharm's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current Return-on-Tangible-Equity is 14.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imexpharm (STC:IMP) Overvalued in 2026?
Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued.
The current stock price of ₫41,200.00 is trading 20.7% below its estimated GF Value™ of ₫51,983.47.
GuruFocus considers Imexpharm to be Modestly Undervalued.
Key valuation signals for STC:IMP:
Return-on-Tangible-Equity: 14.72% (23% above median its 10-year median of 11.93)
GF Value™: ₫51,983.47 vs. price of ₫41,200.00 (20.7% below fair value)
Industry Position: 86.6% above the Drug Manufacturers median (#237 of 897)
No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score
Get the complete analysis for STC:IMP
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:IMP has been successfully added to your 
